Larimar Therapeutics Inc
LRMR
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
69.7% downsideOvervalued by 69.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $311.50 Million |
|---|---|
| Enterprise Value | $137.37 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.27 |
| Beta | 0.82 |
| Outstanding Shares | 85,182,783 |
Return
| Return on Equity | -105.04% |
|---|---|
| Return on Assets | -79.61% |
| Return on Invested Capital | -107.26% |
Valuation & Multiples
| P/E Ratio | -1.87 |
|---|---|
| PEG | -164.73 |
| Price to Sales | - |
| Price to Book Ratio | 3.68 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.8 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6478▲ 52.66% |
|---|---|
| Total Calls | 477,000▲ 230.33% |
| Total Puts | 309,000▲ 1665.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 120.30%▲ 27.47% |
|---|---|
| Total Invested | $394.80M▲ 42.52% |
| Investors Holding | 170▲ 32.00% |
ESG Score
No data
About Larimar Therapeutics Inc
Relevant Senate Committees
Its technical scoring of R&D and Orphan Drug tax incentives directly influences the financial viability and valuation of clinical-stage biotech firms.
Controls Medicare and Medicaid reimbursement policy, drug pricing legislation, and tax credits (like the Orphan Drug Tax Credit) essential to biotech.
Controls the specific funding levels for the FDA and NIH, directly impacting regulatory speed and the availability of research grants.
Directly oversees the FDA and NIH; its legislative actions dictate the drug approval process and federal biomedical research funding.
Oversees intellectual property and patent laws, which are the fundamental value drivers for biotechnology companies like Larimar.
This committee frequently investigates drug pricing and pharmaceutical industry practices, creating significant headline and regulatory risk.